ZIA CP010126 10602 (ZIA) | |||
---|---|---|---|
Title | Kaiser Tamoxifen and Mammographic Density Study | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Benson, Gretchen | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $39,444 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Breast (100.0%) | ||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Endogenous Factors in the Origin and Cause of Cancer |
|||
Abstract | |||
Adjuvant tamoxifen treatment reduces the rates of breast cancer recurrence and breast cancer mortality when compared to placebo; however, many patients still die of their cancers despite tamoxifen treatment. Mammographic density may represent a biosensor of tamoxifen effect. Tamoxifen reduces mammographic density in approximately 50% of users, and a reduction in density of greater than or equal to 10% was associated with a protective effect in a chemoprevention trial of high risk women. Despite evidence that a reduction in density may be a predictor of tamoxifen response, there is little data on the relationship between tamoxifen-related changes in density and breast cancer survival. In this study, we will determine the association between a reduction in mammographic density and breast cancer recurrence or breast cancer death among Kaiser Permanente Northwest (KPNW) ER-positive breast cancer patients treated with tamoxifen, using a nested case-control design. Cases will be women with a recurrence and/or breast cancer-related death, and controls will be sampled from patients who did not recur or die. The mammogram closest to the time of diagnosis but before tamoxifen treatment and the mammogram of the contralateral breast 10 to 18 months after the start of tamoxifen will be digitized and mammographic density will be evaluated. In a subset of ER-positive KPNW patients, we will also examine the long-term patterns of tamoxifen-induced changes in mammographic density, and whether the changes in density persist after treatment ends. Covariate data and breast tumor tissues are also being collected. |